Nasdaq · Common stock
Ultragenyx Pharmaceutical (RARE)
$16.08 +$0.43 (+2.75%)
- Day’s range
- $15.59–$16.22
- Volume
- 3.0M
RARE price history
RARE closed at $16.08 on Oct. 26, 2026. Over the past year, its daily close ranged from $12.88 on Sept. 16, 2026 to $36.54 on Dec. 4, 2025.
Data table: RARE daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $16.08 |
| Oct. 23, 2026 | $15.65 |
| Oct. 22, 2026 | $15.95 |
| Oct. 21, 2026 | $15.92 |
| Oct. 20, 2026 | $16.02 |
| Oct. 19, 2026 | $15.07 |
| Oct. 16, 2026 | $14.54 |
| Oct. 15, 2026 | $15.17 |
| Oct. 14, 2026 | $14.90 |
| Oct. 13, 2026 | $14.92 |
| Oct. 12, 2026 | $15.30 |
| Oct. 9, 2026 | $15.48 |
| Oct. 8, 2026 | $15.29 |
| Oct. 7, 2026 | $14.89 |
| Oct. 6, 2026 | $14.46 |
| Oct. 5, 2026 | $14.50 |
| Oct. 2, 2026 | $15.22 |
| Oct. 1, 2026 | $14.75 |
| Sept. 30, 2026 | $15.03 |
| Sept. 29, 2026 | $15.32 |
| Sept. 28, 2026 | $14.41 |
| Sept. 25, 2026 | $14.50 |
| Sept. 24, 2026 | $14.77 |
| Sept. 23, 2026 | $14.88 |
| Sept. 22, 2026 | $15.62 |
| Sept. 21, 2026 | $14.65 |
| Sept. 18, 2026 | $14.51 |
| Sept. 17, 2026 | $14.50 |
| Sept. 16, 2026 | $12.88 |
| Sept. 15, 2026 | $13.07 |
| Sept. 14, 2026 | $13.61 |
| Sept. 11, 2026 | $14.30 |
| Sept. 10, 2026 | $14.40 |
| Sept. 9, 2026 | $14.31 |
| Sept. 8, 2026 | $14.88 |
| Sept. 4, 2026 | $15.30 |
| Sept. 3, 2026 | $14.85 |
| Sept. 2, 2026 | $26.53 |
| Sept. 1, 2026 | $25.81 |
| Aug. 31, 2026 | $25.21 |
| Aug. 28, 2026 | $25.61 |
| Aug. 27, 2026 | $26.26 |
| Aug. 26, 2026 | $26.44 |
| Aug. 25, 2026 | $26.46 |
| Aug. 24, 2026 | $25.72 |
| Aug. 21, 2026 | $25.83 |
| Aug. 20, 2026 | $25.32 |
| Aug. 19, 2026 | $26.24 |
| Aug. 18, 2026 | $25.49 |
| Aug. 17, 2026 | $26.13 |
| Aug. 14, 2026 | $26.49 |
| Aug. 13, 2026 | $26.38 |
| Aug. 12, 2026 | $26.86 |
| Aug. 11, 2026 | $26.96 |
| Aug. 10, 2026 | $26.80 |
| Aug. 7, 2026 | $25.91 |
| Aug. 6, 2026 | $25.82 |
| Aug. 5, 2026 | $24.93 |
| Aug. 4, 2026 | $25.81 |
| Aug. 3, 2026 | $25.02 |
| July 31, 2026 | $24.91 |
| July 30, 2026 | $26.04 |
| July 29, 2026 | $25.00 |
| July 28, 2026 | $25.98 |
| July 27, 2026 | $26.89 |
| July 24, 2026 | $26.90 |
| July 23, 2026 | $27.02 |
| July 22, 2026 | $27.65 |
| July 21, 2026 | $28.62 |
| July 20, 2026 | $28.53 |
| July 17, 2026 | $29.28 |
| July 16, 2026 | $30.22 |
| July 15, 2026 | $31.71 |
| July 14, 2026 | $32.03 |
| July 13, 2026 | $33.22 |
| July 10, 2026 | $33.82 |
| July 9, 2026 | $34.61 |
| July 8, 2026 | $34.67 |
| July 7, 2026 | $35.87 |
| July 6, 2026 | $33.70 |
| July 2, 2026 | $33.47 |
| July 1, 2026 | $32.38 |
| June 30, 2026 | $33.39 |
| June 29, 2026 | $30.68 |
| June 26, 2026 | $30.77 |
| June 25, 2026 | $29.25 |
| June 24, 2026 | $29.11 |
| June 23, 2026 | $28.76 |
| June 22, 2026 | $29.03 |
| June 18, 2026 | $27.44 |
| June 17, 2026 | $26.91 |
| June 16, 2026 | $24.85 |
| June 15, 2026 | $25.38 |
| June 12, 2026 | $24.35 |
| June 11, 2026 | $23.98 |
| June 10, 2026 | $22.97 |
| June 9, 2026 | $22.79 |
| June 8, 2026 | $21.59 |
| June 5, 2026 | $21.91 |
| June 4, 2026 | $23.31 |
| June 3, 2026 | $22.41 |
| June 2, 2026 | $21.78 |
| June 1, 2026 | $22.85 |
| May 29, 2026 | $23.94 |
| May 28, 2026 | $23.26 |
| May 27, 2026 | $23.39 |
| May 26, 2026 | $23.14 |
| May 22, 2026 | $23.39 |
| May 21, 2026 | $23.71 |
| May 20, 2026 | $23.37 |
| May 19, 2026 | $22.45 |
| May 18, 2026 | $24.19 |
| May 15, 2026 | $25.00 |
| May 14, 2026 | $25.80 |
| May 13, 2026 | $26.46 |
| May 12, 2026 | $26.84 |
| May 11, 2026 | $26.30 |
| May 8, 2026 | $26.12 |
| May 7, 2026 | $26.13 |
| May 6, 2026 | $25.93 |
| May 5, 2026 | $25.01 |
| May 4, 2026 | $24.81 |
| May 1, 2026 | $24.77 |
| April 30, 2026 | $24.69 |
| April 29, 2026 | $24.18 |
| April 28, 2026 | $24.53 |
| April 27, 2026 | $23.99 |
| April 24, 2026 | $24.10 |
| April 23, 2026 | $24.28 |
| April 22, 2026 | $24.61 |
| April 21, 2026 | $24.10 |
| April 20, 2026 | $25.06 |
| April 17, 2026 | $24.81 |
| April 16, 2026 | $24.52 |
| April 15, 2026 | $25.18 |
| April 14, 2026 | $24.57 |
| April 13, 2026 | $23.63 |
| April 10, 2026 | $23.30 |
| April 9, 2026 | $23.91 |
| April 8, 2026 | $23.15 |
| April 7, 2026 | $23.15 |
| April 6, 2026 | $22.87 |
| April 2, 2026 | $22.45 |
| April 1, 2026 | $21.42 |
| March 31, 2026 | $20.95 |
| March 30, 2026 | $19.30 |
| March 27, 2026 | $19.38 |
| March 26, 2026 | $20.00 |
| March 25, 2026 | $19.85 |
| March 24, 2026 | $18.50 |
| March 23, 2026 | $20.27 |
| March 20, 2026 | $19.87 |
| March 19, 2026 | $20.42 |
| March 18, 2026 | $20.46 |
| March 17, 2026 | $21.60 |
| March 16, 2026 | $21.82 |
| March 13, 2026 | $21.34 |
| March 12, 2026 | $21.71 |
| March 11, 2026 | $22.21 |
| March 10, 2026 | $22.84 |
| March 9, 2026 | $22.61 |
| March 6, 2026 | $21.25 |
| March 5, 2026 | $21.46 |
| March 4, 2026 | $21.80 |
| March 3, 2026 | $22.07 |
| March 2, 2026 | $23.02 |
| Feb. 27, 2026 | $23.39 |
| Feb. 26, 2026 | $23.04 |
| Feb. 25, 2026 | $22.91 |
| Feb. 24, 2026 | $22.75 |
| Feb. 23, 2026 | $22.51 |
| Feb. 20, 2026 | $22.72 |
| Feb. 19, 2026 | $21.83 |
| Feb. 18, 2026 | $20.45 |
| Feb. 17, 2026 | $20.18 |
| Feb. 13, 2026 | $20.52 |
| Feb. 12, 2026 | $23.50 |
| Feb. 11, 2026 | $23.88 |
| Feb. 10, 2026 | $24.20 |
| Feb. 9, 2026 | $23.88 |
| Feb. 6, 2026 | $24.70 |
| Feb. 5, 2026 | $23.79 |
| Feb. 4, 2026 | $24.69 |
| Feb. 3, 2026 | $24.80 |
| Feb. 2, 2026 | $24.76 |
| Jan. 30, 2026 | $24.07 |
| Jan. 29, 2026 | $24.27 |
| Jan. 28, 2026 | $24.44 |
| Jan. 27, 2026 | $24.62 |
| Jan. 26, 2026 | $24.31 |
| Jan. 23, 2026 | $24.21 |
| Jan. 22, 2026 | $23.40 |
| Jan. 21, 2026 | $22.75 |
| Jan. 20, 2026 | $22.63 |
| Jan. 16, 2026 | $22.49 |
| Jan. 15, 2026 | $23.50 |
| Jan. 14, 2026 | $24.07 |
| Jan. 13, 2026 | $24.11 |
| Jan. 12, 2026 | $24.37 |
| Jan. 9, 2026 | $22.51 |
| Jan. 8, 2026 | $23.21 |
| Jan. 7, 2026 | $24.20 |
| Jan. 6, 2026 | $22.54 |
| Jan. 5, 2026 | $23.11 |
| Jan. 2, 2026 | $23.60 |
| Dec. 31, 2025 | $23.00 |
| Dec. 30, 2025 | $22.78 |
| Dec. 29, 2025 | $19.72 |
| Dec. 26, 2025 | $34.19 |
| Dec. 24, 2025 | $34.58 |
| Dec. 23, 2025 | $34.13 |
| Dec. 22, 2025 | $34.75 |
| Dec. 19, 2025 | $33.50 |
| Dec. 18, 2025 | $32.84 |
| Dec. 17, 2025 | $33.21 |
| Dec. 16, 2025 | $34.34 |
| Dec. 15, 2025 | $36.23 |
| Dec. 12, 2025 | $36.23 |
| Dec. 11, 2025 | $36.20 |
| Dec. 10, 2025 | $36.00 |
| Dec. 9, 2025 | $36.30 |
| Dec. 8, 2025 | $36.45 |
| Dec. 5, 2025 | $36.38 |
| Dec. 4, 2025 | $36.54 |
| Dec. 3, 2025 | $36.45 |
| Dec. 2, 2025 | $33.47 |
| Dec. 1, 2025 | $33.37 |
| Nov. 28, 2025 | $34.75 |
| Nov. 26, 2025 | $33.76 |
| Nov. 25, 2025 | $33.53 |
| Nov. 24, 2025 | $32.78 |
| Nov. 21, 2025 | $33.59 |
| Nov. 20, 2025 | $31.18 |
| Nov. 19, 2025 | $31.86 |
| Nov. 18, 2025 | $32.83 |
| Nov. 17, 2025 | $32.54 |
| Nov. 14, 2025 | $33.08 |
| Nov. 13, 2025 | $32.90 |
| Nov. 12, 2025 | $33.53 |
| Nov. 11, 2025 | $33.25 |
| Nov. 10, 2025 | $31.94 |
| Nov. 7, 2025 | $30.63 |
| Nov. 6, 2025 | $30.95 |
| Nov. 5, 2025 | $31.87 |
| Nov. 4, 2025 | $32.46 |
| Nov. 3, 2025 | $33.47 |
| Oct. 31, 2025 | $34.60 |
| Oct. 30, 2025 | $35.17 |
| Oct. 29, 2025 | $34.59 |
| Oct. 28, 2025 | $34.77 |
| Oct. 27, 2025 | $35.31 |
Key figures
- 52-week range
- $12.88–$36.54Low Sept. 16, 2026; high Dec. 4, 2025
- Average daily volume
- 4.2MPast 3 months
- Market value
- $1.59B
- Dividend yield
- —
- From 52-week high
- −55.99%
Price change
- 1 month
- +10.90%
- 3 months
- −40.22%
- Year to date
- −30.09%
- 1 year
- −52.04%
$1,000 a year ago
$1,000 put into RARE at the close on Oct. 24, 2025 would be worth $480.
Price only, dividends not included.
What Wall Street says about RARE
In the past 90 days, Wall Street firms published 32 rating or price-target actions on RARE: 4 downgrades, 1 new rating, 1 reiterated rating, 14 raised price targets and 12 lowered price targets.
| Action | Rating | |||
|---|---|---|---|---|
| UBS | Initiates coverage | Neutral | $16 | |
| Barclays | Raises target | Overweight | $32 to $35 | |
| Evercore ISI Group | Raises target | In-line | $16 to $18 | |
| Canaccord Genuity | Raises target | Buy | $37 to $39 | |
| Cantor Fitzgerald | Raises target | Overweight | $33 to $39 | |
| Citigroup | Raises target | Buy | $31 to $32 | |
| Morgan Stanley | Raises target | Equal-weight | $18 to $20 | |
| Citigroup | Raises target | Buy | $28 to $31 | |
| Barclays | Cuts target | Overweight | $43 to $32 | |
| Goldman Sachs | Cuts target | Neutral | $28 to $19 | |
| Baird | Downgrade | Outperform to Neutral | $40 to $16 | |
| Canaccord Genuity | Cuts target | Buy | $83 to $37 | |
| Cantor Fitzgerald | Cuts target | Overweight | $103 to $33 | |
| Citigroup | Cuts target | Buy | $58 to $28 | |
| Evercore ISI Group | Downgrade | Outperform to In-line | $34 to $16 | |
| HC Wainwright & Co. | Cuts target | Buy | $50 to $25 | |
| Jefferies | Cuts target | Buy | $77 to $28 | |
| JP Morgan | Downgrade | Overweight to Neutral | $80 to $36 | |
| TD Cowen | Cuts target | Buy | $49 to $18 | |
| Wedbush | Cuts target | Neutral | $30 to $23 | |
| Wells Fargo | Cuts target | Overweight | $50 to $18 | |
| William Blair | Downgrade | Outperform to Market perform | — | |
| Wells Fargo | Raises target | Overweight | $46 to $50 | |
| JP Morgan | Raises target | Overweight | $75 to $80 | |
| Morgan Stanley | Raises target | Overweight | $67 to $74 | |
| Canaccord Genuity | Raises target | Buy | $81 to $83 | |
| Cantor Fitzgerald | Raises target | Overweight | $96 to $103 | |
| Citigroup | Raises target | Buy | $45 to $58 | |
| Wells Fargo | Raises target | Overweight | $45 to $46 | |
| HC Wainwright & Co. | Reiterates | Buy | $50 | |
| Wells Fargo | Cuts target | Overweight | $47 to $45 | |
| Guggenheim | Cuts target | Buy | $43 to $35 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
- Headquarters
- Novato, Calif.
- Employees
- 1,371
- Listed
- Jan. 31, 2014
- Sector
- Health care
- Industry
- Pharmaceutical preparations
In WallStreetDigest editions
No WallStreetDigest article about RARE is on the site yet.